Dr Bridget Draper
Senior Research Officer
Background
Bridget works as a Senior Research Officer in the Disease Elimination program, with a specific focus on viral hepatitis projects in low- and middle-income countries. She currently works on the TREAT-HEP Myanmar project and the HepC CUTTS project.
Bridget completed a Bachelor of Arts (International Studies) at RMIT and her honours in Health Sciences through Monash University at the Burnet Institute. Her honours project focussed on acceptability of HIV pre-exposure prophylaxis among men who have sex with men in Myanmar. In 2022, Bridget completed her PhD exploring how to provide hepatitis C testing and treatment in resource-constrained settings using implementation science and health service delivery research methods.
Her work involved evaluating hepatitis C treatment programs in specialist and primary care settings in Myanmar, including the CT2 Study and evaluation of the National Hepatitis Control Program.
Qualifications
- 2022: Doctor of Philosophy, Monash University, Australia
- 2015: Honours (Health Sciences), Monash University, Australia
- 2014: Bachelor of Arts (International Studies), RMIT, Australia
Burnet publications
View 28 morePatients’ experience of accessing hepatitis C treatment through the Myanmar national hepatitis C treatment program: a qualitative evaluation
BMC Health Services Research
Bridget Draper et al
The National Naloxone Reference Group: A collective voice on take‐home naloxone policy and practice in Australia
Drug and Alcohol Review
Paul Dietze et al
Cost‐effectiveness of a decentralized, community‐based “one‐stop‐shop” hepatitis C testing and treatment program in Yangon, Myanmar
JGH Open
Thin Mar Win et al
Current projects
CUTTS HepC: Catalysing uptake of under-utilised tools & treatment simplification for HepC
This project will generate evidence on how to improve hepatitis C prevention and care for people who inject drugs in low-and middle-income countries.
TREAT-HEP: community-based viral hepatitis testing and treatment project in Yangon, Myanmar
This project delivers hepatitis C prevention, testing and treatment services and hepatitis B testing and vaccination services.
Past projects
View 1 more
Eliminate C (EC) Victoria partnership
A partnership aimed at increasing hepatitis C treatment uptake among people who inject drugs (PWID) using nurse-led models of care in community and prison settings.
Hepatitis C: Community Testing and Treatment (CT2)
This study examined the feasibility of a community-based testing and treatment program for hepatitis C.
Rapid-EC hepatitis C Pilot Study
The introduction of direct-acting antiviral (DAA) therapies has meant the elimination of hepatitis C as a public health issue in Australia is a very real possibility. The challenge that remains is to ensure that all people living with HCV can access testing to become aware of their status and then get treated and cured.
News and features
View 5 more
Australia Awards Fellows join Burnet to improve outcomes for people with hepatitis C
We welcomed Australia Awards Fellowships delegates from Myanmar and Tanzania in July to learn more about the prevention, treatment and testing of hepatitis C and harm reduction for people who inject drugs.
New treatment pathways for hepatitis C
Newly published Burnet study demonstrates the feasibility and effectiveness of simplified treatment of hepatitis C in Myanmar.
Burnet is part of global effort to prevent hepatitis C
Burnet Institute and partners have received US$31 million from global health agency Unitaid for an international harm reduction program.